(Q34267502)

1 August 2017

title

Critical effect sizes in toxicological risk assessment: a comprehensive and critical evaluation (English)

1 reference

1 August 2017

S Dekkers

1

0 references

author name string

C de Heer

series ordinal

2

1 reference

1 August 2017

M A.J. Rennen

series ordinal

3

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Environmental Toxicology and Pharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

10

1 reference

1 August 2017

issue

1-2

1 reference

1 August 2017

page(s)

33-52

1 reference

Dose-response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Dose-response assessment for developmental toxicity. III. Statistical models

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Benchmark dose analysis of developmental toxicity in rats exposed to boric acid.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Calculation of benchmark doses for reproductive and developmental toxicity observed after exposure to isopropanol.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Negative selection in hepatic tumor promotion in relation to cancer risk assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Estimating benchmark concentrations and other noncancer endpoints in epidemiology studies

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Benchmark Dose Workshop: Criteria for Use of a Benchmark Dose to Estimate a Reference Dose

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Alternatives for a risk assessment on chronic noncancer effects from oral exposure to trichloroethylene.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Improvements in quantitative noncancer risk assessment. Sponsored by the Risk Assessment Specialty Section of the Society of Toxicology

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Comparing the results of a Monte Carlo analysis with EPA's reasonable maximum exposed individual (RMEI): a case study of a former wood treatment site

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

A new method for determining allowable daily intakes.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Reanalysis of dose-response data from the Iraqi methylmercury poisoning episode

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Influence of prenatal mercury exposure upon scholastic and psychological test performance: benchmark analysis of a New Zealand cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

The EPA health risk assessment of methylcyclopentadienyl manganese tricarbonyl (MMT).

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Application of benchmark dose risk assessment methodology to developmental toxicity: an industrial view.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

A comparison of methods for estimating the benchmark dose based on overdispersed data from developmental toxicity studies

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Incidence of developmental defects at the no observed adverse effect level (NOAEL)

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Risk assessment of nongenotoxic carcinogens based upon cell proliferation/death rates in rodents.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Procedures for calculating benchmark doses for health risk assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Application of the Benchmark Method to Risk Assessment of Trichloroethene

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

A simulation study of the influence of study design on the estimation of benchmark doses for developmental toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

The application of benchmark dose methodology to data from prenatal developmental toxicity studies

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Neurotoxicity modeling for risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Estimation of a chromium inhalation reference concentration using the benchmark dose method: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Developmental toxicity of carbendazim: comparison of no-observed-adverse-effect level and benchmark dose approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Application of a biologically-based RFD estimation method to tetrachlorodibenzo-p-dioxin (TCDD) mediated immune suppression and enzyme induction

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Characterizing dose-response: I: Critical assessment of the benchmark dose concept

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Selective vulnerability of dopaminergic systems to industrial chemicals: risk assessment of related neuroendocrine changes.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Comparing alternative approaches to establishing regulatory levels for reproductive toxicants: DBCP as a case study

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

An approach for modeling noncancer dose responses with an emphasis on uncertainty.

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Biologically Based, Quantitative Risk Assessment of Neurotoxicants

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Biologically-based dose-response model for neurotoxicity risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Assessment factors for human health risk assessment: a discussion paper

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

Effect of subchronic 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on immune system and target gene responses in mice: calculation of benchmark doses for CYP1A1 and CYP1A2 related enzyme activities

1 reference

https://api.crossref.org/works/10.1016%2FS1382-6689%2801%2900068-0

7 January 2021

10.1016/S1382-6689(01)00068-0

Identifiers

DOI

1 reference

1 August 2017

1 reference